Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy, Radiotherapy and rhGM-CSF in Oligometastatic NSCLC
NCT03489616Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2018
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of sargramostim in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
sargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03489616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489616.